Understand the source comparison
GHRP-6 Acetate Results Timeline: Phase Comparison
The table below summarizes the GHRP-6 acetate results timeline across immediate, subacute, and chronic phases. Understanding which biomarkers to measure at each phase prevents mistiming assays and misinterpreting outcomes. Immediate Phase 0–90 minutes GHS-R1a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The table below summarizes the GHRP-6 acetate results timeline across immediate, subacute, and chronic phases. Understanding which biomarkers to measure at each phase prevents mistiming assays and misinterpreting outcomes.
- Immediate Phase
- 0–90 minutes
- GHS-R1a receptor activation → pituitary GH release
- Serum GH (peak 30–60 min), hunger onset (10–20 min)
- 5- to 8-fold GH increase at 100 mcg/kg dose
- Confirms peptide bioactivity; not predictive of tissue outcomes
- Subacute Phase
- Days 1–14
- Hepatic IGF-1 synthesis in response to GH pulse
- Serum IGF-1 (peaks day 3–5), nitrogen retention (day 4–6)
- 30–50% IGF-1 elevation above baseline by day 5
- Requires 2–3x daily dosing to sustain; single doses produce transient response
- Chronic Phase
- Weeks 4–12
- IGF-1-mediated tissue remodeling (mTOR, collagen synthesis)
- Lean mass (DEXA), fat mass (DEXA), tissue histology
- 8–10% lean mass gain, 10–15% fat mass reduction by week 12
- Results plateau by week 10–12; earlier endpoints miss peak efficacy